Sana Biotechnology, Inc.

NasdaqGS:SANA Lagerbericht

Marktkapitalisierung: US$953.7m

Sana Biotechnology Management

Management Kriterienprüfungen 3/4

Sana Biotechnology CEO ist Steve Harr , ernannt in Sep 2018, hat eine Amtszeit von 7.83 Jahren. Die jährliche Gesamtvergütung beträgt $2.90M , bestehend aus 24% Gehalt und 76% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.99% der Aktien des Unternehmens, im Wert von $28.50M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.9 Jahre bzw. 7.7 Jahre.

Wichtige Informationen

Steve Harr

Geschäftsführender

US$2.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts23.98%
Amtszeit als Geschäftsführer7.8yrs
Eigentum des Geschäftsführers3.0%
Durchschnittliche Amtszeit des Managements1.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.7yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha
Analyseartikel • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha
Analyseartikel • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyseartikel • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.
Analyseartikel • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Feb 12

Sana Biotechnology: Exciting Preclinical Science

Sana was formed by founders of Juno. It has very exciting science and encouraging preclinical data. However, risks abound.
Analyseartikel • Oct 13

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Sana Biotechnology...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Steve Harr im Vergleich zu den Einnahmen von Sana Biotechnology verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$242m

Dec 31 2025US$3mUS$696k

-US$244m

Sep 30 2025n/an/a

-US$234m

Jun 30 2025n/an/a

-US$252m

Mar 31 2025n/an/a

-US$209m

Dec 31 2024US$9mUS$681k

-US$267m

Sep 30 2024n/an/a

-US$306m

Jun 30 2024n/an/a

-US$245m

Mar 31 2024n/an/a

-US$309m

Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

Vergütung im Vergleich zum Markt: SteveDie Gesamtvergütung ($USD2.90M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.63M).

Entschädigung vs. Einkommen: SteveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Steve Harr (56 yo)

7.8yrs
Amtszeit
US$2,903,010
Vergütung

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Steven Harr
President7.8yrsUS$2.90m2.99%
$ 28.5m
Brian Piper
Executive VP & CFOless than a yearkeine Datenkeine Daten
Susan Wyrick
Treasurer1.8yrskeine Daten0.065%
$ 623.9k
Snehal Patel
Senior VP & Chief Technical Officer2.5yrskeine Datenkeine Daten
Dhavalkumar Patel
Executive VP & Chief Scientific Officer1.9yrskeine Daten0.033%
$ 316.4k
Aaron Grossman
Executive VPless than a yearkeine Datenkeine Daten
Debra Wisdom
VP & Head of Peopleno datakeine Datenkeine Daten
Gary Meininger
Chief Medical Officer3.3yrskeine Datenkeine Daten
Yuko Soneoka
Head of Intellectual Property1.9yrskeine Datenkeine Daten
John Gerecitano
Head of Oncology Research & Development1.9yrskeine Datenkeine Daten
1.9yrs
Durchschnittliche Betriebszugehörigkeit
54yo
Durchschnittliches Alter

Erfahrenes Management: SANADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Steven Harr
President7.8yrsUS$2.90m2.99%
$ 28.5m
Robert Taylor Nelsen
Independent Director7.8yrsUS$162.79k0.0046%
$ 44.1k
Yuhmin Yang
Independent Director7.8yrsUS$167.79k0.050%
$ 474.6k
Michelle Seitz
Independent Director5.7yrsUS$182.79k0%
$ 0
Richard Mulligan
Vice Chairman7.7yrsUS$162.79k0.90%
$ 8.6m
Hans Edgar Bishop
Independent Chairman of the Board7.8yrsUS$220.51k1.95%
$ 18.6m
Joshua Bilenker
Independent Director5.6yrsUS$169.52k0.0067%
$ 63.6k
Alise Reicin
Independent Director5.6yrsUS$170.29k0%
$ 0
Robert Rosiello
Independent Director1.1yrsUS$230.70k0%
$ 0
7.7yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter

Erfahrener Vorstand: SANADie Vorstandsmitglieder gelten als erfahren (7.7 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/07/26 04:17
Aktienkurs zum Tagesende2026/07/24 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sana Biotechnology, Inc. wird von 12 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc
Reni BenjaminCitizens JMP Securities, LLC